SCHEMBL7207115

SCHEMBL7207115

CC(C)(C)OC(=O)n1cc(-c2cc(Nc3ccccc3)n[nH]2)c2ccccc21

nearest known ligand 0.44

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
PIM1 P11309 1/20 0.44
MARK3 P27448 1/20 0.44
MAP4K2 Q12851 1/20 0.44
CAMK2B Q13554 1/20 0.44
PIM3 Q86V86 1/20 0.44
PIM2 Q9P1W9 1/20 0.44
BRD4 O60885 1/20 0.42
CREBBP Q92793 1/20 0.42
L3MBTL1 Q9Y468 1/20 0.42
MEN1 O00255 3/20 0.40
KMT2A Q03164 3/20 0.40
CHEK1 O14757 1/20 0.40
ACHE P22303 1/20 0.39
PDE10A Q9Y233 1/20 0.39
PAK4 O96013 1/20 0.39
CSNK2A2 P19784 1/20 0.39
AKT1 P31749 1/20 0.39
PLK1 P53350 1/20 0.39
CSNK2B P67870 1/20 0.39
CSNK2A1 P68400 1/20 0.39

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL7204720 0.89 CDK2 (0.47) PIM1MARK3MAP4K2CAMK2BPIM3
SCHEMBL21262418 0.84 TNIK (0.55)
SCHEMBL29965821 0.84 TNIK (0.55)
SCHEMBL29965861 0.83 TNIK (0.57) PIM1MARK3MAP4K2CAMK2BPIM3
SCHEMBL21262419 0.83 TNIK (0.57) PIM1MARK3MAP4K2CAMK2BPIM3
SCHEMBL27257521 0.72 L3MBTL1 (0.53) PIM1MARK3MAP4K2CAMK2BPIM3
SCHEMBL30620463 0.69 L3MBTL1 (0.50) PIM1MARK3MAP4K2CAMK2BPIM3
SCHEMBL14222808 0.69 L3MBTL1 (0.57) PIM1MARK3MAP4K2CAMK2BPIM3
SCHEMBL20033885 0.69 L3MBTL1 (0.57) PIM1MARK3MAP4K2CAMK2BPIM3
SCHEMBL29236564 0.69 L3MBTL1 (0.57) PIM1MARK3MAP4K2CAMK2BPIM3

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1274706-A1 PYRAZOLES FOR INHIBITING PROTEIN KINASES AGOURON PHARMACEUTICALS, INC. (US) 2003-01-15 EP disclosed
US-6462069-B2 KINASE INHIBITORS; ANTICANCER AGENTS AGOURON PHARMACEUTICALS, INC. 2002-10-08 US disclosed
WO-2001079198-A9 PYRAZOLES FOR INHIBITING PROTEIN KINASE AGOURON PHARMA (US) 2002-05-16 WO disclosed
US-20020006952-A1 Compounds, pharmaceutical compositions, and methods for inhibiting protein kinases LIGHPOINTE COMMUNICATION, INC. 2002-01-17 US disclosed
WO-2001079198-A1 PYRAZOLES FOR INHIBITING PROTEIN KINASE AGOURON PHARMACEUTICALS, INC. (US) 2001-10-25 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20020006952-A1 Compounds, pharmaceutical compositions, and methods for inhibiting protein kinases CDK3, CCNK, CDK1 PIM1 450/4885MARK3 263/4885MAP4K2 65/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.